Details for Patent: 10,857,148
✉ Email this page to a colleague
Which drugs does patent 10,857,148 protect, and when does it expire?
Patent 10,857,148 protects INGREZZA and is included in one NDA.
This patent has thirteen patent family members in ten countries.
Summary for Patent: 10,857,148
| Title: | Methods for the administration of certain VMAT2 inhibitors |
| Abstract: | Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-.alpha.-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2- ,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin. |
| Inventor(s): | O'Brien; Christopher F. (San Diego, CA), Bozigian; Haig P. (San Diego, CA) |
| Assignee: | Neurocrine Biosciences, Inc. (San Deigo, CA) |
| Application Number: | 16/871,528 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Recent additions to Drugs Protected by US Patent 10,857,148
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,857,148
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Try a Trial | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Try a Trial | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,857,148
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017435893 | ⤷ Try a Trial | |||
| Canada | 3077149 | ⤷ Try a Trial | |||
| China | 111836543 | ⤷ Try a Trial | |||
| China | 116492340 | ⤷ Try a Trial | |||
| Eurasian Patent Organization | 202090932 | ⤷ Try a Trial | |||
| Japan | 2021193146 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
